EQ 300 by Dragon Pharma

Dragon Pharma Original Formula

Boldenone Undecylenate

EQ 300300 mg/ml
Ester Undecylenate
Half-Life ~14 days
Anabolic Ratio 100
Androgenic Ratio 50
Carrier MCT Oil
Form Injection, 10ml
Availability: In Stock
$66.00
Quantity
Shipping
Wishlist

Boldenone Undecylenate — EQ 300 by Dragon Pharma

EQ 300 is Dragon Pharma's formulation of injectable Boldenone Undecylenate at 300mg/ml — originally developed as a veterinary steroid for horses, Boldenone is structurally a testosterone molecule with an added 1,2-double bond that fundamentally changes its behaviour in the human body. Each 10ml vial in Dragon Pharma's MCT oil carrier provides sustained release over its long Undecylenate ester, suited to extended cycles of 14 weeks or more.

Also searched as: Boldenone Undecylenate 300mg, EQ 300, Equipoise Dragon Pharma, Boldenone steroid.

What Is Boldenone Undecylenate (Equipoise)?

Boldenone is structurally testosterone with a C1-C2 double bond added — a modification that produces several important differences from testosterone despite structural similarity:

Property Boldenone (EQ) Testosterone (comparison)
Aromatisation rate ~50% of testosterone's rate Baseline reference
DHT conversion Converts to DHB (dihydroboldenone) — weaker than DHT Converts to DHT — strong androgen
Androgenic rating 50 100
Anabolic rating 100 100
Erythropoiesis stimulation Strong — significantly increases RBC production Moderate
Appetite stimulation Pronounced — one of the strongest appetite increases of any AAS Moderate
Ester half-life ~14 days (Undecylenate) ~7-8 days (Enanthate)

The RBC Elevation Mechanism — EQ's Most Distinctive Property

Boldenone's pronounced stimulation of red blood cell production (erythropoiesis) is its most clinically distinctive property and a genuine information gap in most competitor content:

  • Boldenone stimulates erythropoietin (EPO) production in the kidneys — the same mechanism as exogenous EPO used in endurance sports
  • The resulting increase in red blood cell count and haematocrit improves oxygen delivery to muscle tissue, contributing to improved endurance and training capacity alongside its anabolic effects
  • This haematocrit elevation is dose-dependent — at higher doses or longer cycles, haematocrit can reach levels requiring intervention (blood donation is sometimes used to manage this)
  • Haematocrit above ~52-54% is associated with increased blood viscosity and cardiovascular risk — monitoring via bloodwork is more important with EQ than with most other injectable compounds
  • This unique mechanism is why EQ appears in WADA testing for endurance-enhancement alongside its use as an anabolic AAS

Why EQ Requires Longer Cycles Than Most Injectable Steroids

The Undecylenate ester is longer than the commonly used Enanthate or Cypionate esters — approximately 14 days versus 7-8 days half-life:

  • Time to reach steady-state blood levels = approximately 4-5 × half-life = 56-70 days (8-10 weeks) just to stabilise
  • A 10-week cycle leaves only ~2 weeks of work at stable levels — most experienced EQ users run 14-16 weeks minimum
  • Many users start EQ several weeks before other long-ester compounds specifically to account for its slow build
  • Conversely, EQ blood levels remain detectable for an extended period after stopping — the WADA detection window for Boldenone is among the longest of any AAS, documented at 5+ months in some cases

Effects and Benefits

  • Steady, gradual lean mass gains with lower water retention than testosterone at equivalent doses
  • Pronounced appetite stimulation — one of the most significant appetite increases of any AAS, making EQ particularly useful in caloric surplus phases
  • Improved endurance and work capacity through RBC elevation and increased haematocrit
  • Lower androgenic activity than testosterone — favourable anabolic-to-androgenic ratio
  • Lower aromatisation rate than testosterone, reducing estrogen management demands

Side Effects

  • Haematocrit elevation — the most EQ-specific concern, requiring periodic bloodwork; values above 52-54% warrant attention
  • Significant suppression of natural testosterone production — Post Cycle Therapy is required, with timing adjusted for EQ's long ester
  • Aromatisation at approximately 50% the rate of testosterone — estrogen management via an aromatase inhibitor such as Arimidex may be needed at higher doses
  • Very long detection window — documented at 5+ months for WADA testing, relevant for tested athletes
  • The pronounced appetite increase is a benefit for bulking but can be difficult to manage for users trying to maintain a caloric deficit

EQ 300 vs Equipoise 500

Dragon Pharma offers Boldenone Undecylenate in two concentrations:

  • EQ 300 (300mg/ml) — standard concentration, suited to most protocols and easier to dose precisely at lower-to-moderate weekly amounts
  • Equipoise 500 (500mg/ml) — for advanced users running higher weekly doses who want to minimise injection volume across an extended 14-16 week cycle

Building a Cycle Around EQ 300

  • Enantat 250 or Cypionat 250 as the testosterone base — start EQ 2-4 weeks before other compounds to account for slow build
  • Arimidex on hand for estrogen management at higher doses
  • Clomid or Nolvadex for Post Cycle Therapy, started later than with shorter esters to account for EQ's extended clearance

"EQ 300 is formulated in MCT oil for smooth delivery of this long-ester compound, designed for the extended 14-16 week cycles that allow Boldenone Undecylenate to reach its full potential."

Storage and Handling

Store EQ 300 at room temperature, away from direct sunlight and heat. Use sterile technique for every draw — a fresh needle for drawing and a separate needle for injection is recommended.

Please log in to write review.

Boldenone stimulates erythropoietin (EPO) production in the kidneys more strongly than most other AAS — EPO then drives increased red blood cell production. This mechanism is similar to exogenous EPO used in endurance sports, and is why EQ produces a more pronounced haematocrit increase than testosterone at equivalent doses.

A minimum of 14 weeks, with 16 weeks preferred. The Undecylenate ester's ~14-day half-life means steady-state blood levels aren't reached until approximately 8-10 weeks into the cycle — a 10-week cycle leaves insufficient time at effective levels to justify EQ's inclusion.

Later than with shorter-ester compounds. Due to EQ's long half-life, blood levels remain elevated for several weeks after the last injection. PCT is typically started 3-4 weeks after the last EQ injection, compared to 2 weeks for Testosterone Enanthate.

No — Boldenone aromatises at approximately 50% the rate of testosterone, producing less estrogen-driven water retention. EQ is associated with steadier, drier lean mass gains compared to testosterone at comparable doses.

Haematocrit above approximately 52-54% is generally where concerns around blood viscosity and cardiovascular risk increase. Periodic bloodwork during an EQ cycle is more important than with most other injectable compounds due to EQ's pronounced erythropoietic activity.

Boldenone has one of the longest WADA detection windows of any commonly used AAS — documented at 5+ months in some cases. This is significantly longer than most testosterone esters and is an important consideration for tested athletes.